Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in

See also
Status	Clinical Trial	Phase
Terminated	`NCT01290393` - Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
Completed	`NCT00369824` - Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects	Phase 3
Completed	`NCT00345878` - Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years	Phase 3
Completed	`NCT00947115` - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects	Phase 3
Completed	`NCT01187927` - Drug Use Investigation for Cervarix®	N/A
Completed	`NCT00169494` - Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18	Phase 3
Completed	`NCT01190176` - Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects	Phase 3
Completed	`NCT00359619` - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine	Phase 2
Completed	`NCT00196937` - Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18	Phase 3
Completed	`NCT00534638` - Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents	Phase 4
Completed	`NCT00250276` - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.	Phase 3
Completed	`NCT01031069` - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females	Phase 4
Completed	`NCT00996125` - Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects	Phase 3
Completed	`NCT00779766` - Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects	Phase 3
Completed	`NCT01953822` - Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom	N/A
Completed	`NCT01153906` - Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination	N/A
Completed	`NCT01207999` - Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer	N/A
Completed	`NCT00693615` - Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females	Phase 2
Completed	`NCT00693966` - Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females	Phase 2
Completed	`NCT00541970` - Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs	Phase 1

NCT number	NCT00799825
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	January 1, 2009
Completion date	August 2, 2012

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms